Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 - PubMed (original) (raw)
Clinical Trial
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al. J Clin Oncol. 2008.
Abstract
Purpose: The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although primary radiation therapy with concurrent chemotherapy produces similar results. As both have curative potential, there has been great interest in the use of trimodality therapy. To this end, we compared survival, response, and patterns of failure of trimodality therapy to esophagectomy alone in patients with nonmetastatic esophageal cancer.
Patients and methods: Four hundred seventy-five eligible patients were planned for enrollment. Patients were randomly assigned to either esophagectomy with node dissection alone or cisplatin 100 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 4 days on weeks 1 and 5 concurrent with radiation therapy (50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection.
Results: Fifty-six patients were enrolled between October 1997 and March 2000, when the trial was closed due to poor accrual. Thirty patients were randomly assigned to trimodality therapy and 26 were assigned to surgery alone. Patient and tumor characteristics were similar between groups. Treatment was generally well tolerated. Median follow-up was 6 years. An intent-to-treat analysis showed a median survival of 4.48 v 1.79 years in favor of trimodality therapy (exact stratified log-rank, P = .002). Five-year survival was 39% (95% CI, 21% to 57%) v 16% (95% CI, 5% to 33%) in favor of trimodality therapy.
Conclusion: The results from this trial reflect a long-term survival advantage with the use of chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support trimodality therapy as a standard of care for patients with this disease.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest.
Figures
Fig 1
CONSORT diagram.
Fig 2
Kaplan-Meier estimates of overall survival (OS) by treatment arm measured from study entry until death from any cause. (*) NE, not estimable. †Asymptotic results for OS were comparable to those obtained using the exact method.
Fig 3
Kaplan-Meier estimates of progression-free survival (PFS) by treatment arm measured from study entry until documented progression of disease or death from any cause. (*) NE, not estimable. †Asymptotic results for PFS were comparable to those obtained using the exact method.
Comment in
- Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
Pereira B, Gourgou-Bourgade S, Azria D, Ychou M. Pereira B, et al. J Clin Oncol. 2008 Nov 1;26(31):5133-4; author reply 5134. doi: 10.1200/JCO.2008.19.0322. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838699 No abstract available.
Similar articles
- Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J, Xu W, Ringash J, Keshavjee S, Chen E, Haider M, Darling G. Knox JJ, et al. Cancer. 2010 Sep 1;116(17):4023-32. doi: 10.1002/cncr.25349. Cancer. 2010. PMID: 20533506 Clinical Trial. - Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Kleinberg L, et al. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34. doi: 10.1016/s0360-3016(02)04598-4. Int J Radiat Oncol Biol Phys. 2003. PMID: 12738305 Clinical Trial. - Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D. Hategan M, et al. Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Dis Esophagus. 2015. PMID: 24863560 Review. - Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Jin J, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380576 - Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Bates BA, et al. J Clin Oncol. 1996 Jan;14(1):156-63. doi: 10.1200/JCO.1996.14.1.156. J Clin Oncol. 1996. PMID: 8558191 Review.
Cited by
- Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage.
Luna RA, Dolan JP, Diggs BS, Bronson NW, Sheppard BC, Schipper PH, Tieu BH, Feeney BT, Gatter KM, Vaccaro GM, Thomas CR Jr, Hunter JG. Luna RA, et al. J Gastrointest Surg. 2015 Jul;19(7):1201-7. doi: 10.1007/s11605-015-2821-4. Epub 2015 Apr 25. J Gastrointest Surg. 2015. PMID: 25910454 - Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008.
Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Worni M, et al. J Am Coll Surg. 2012 Nov;215(5):643-51. doi: 10.1016/j.jamcollsurg.2012.07.006. J Am Coll Surg. 2012. PMID: 23084493 Free PMC article. - A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. Larue RT, et al. BMC Cancer. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z. BMC Cancer. 2016. PMID: 27535748 Free PMC article. Clinical Trial. - A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.
Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. Lin SH, et al. J Gastrointest Oncol. 2015 Feb;6(1):45-52. doi: 10.3978/j.issn.2078-6891.2014.054. J Gastrointest Oncol. 2015. PMID: 25642337 Free PMC article. - Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.
Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Rees J, et al. Br J Cancer. 2015 Aug 11;113(4):603-10. doi: 10.1038/bjc.2015.258. Epub 2015 Jul 23. Br J Cancer. 2015. PMID: 26203761 Free PMC article. Clinical Trial.
References
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. - PubMed
- Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730. - PubMed
- Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol. 1996;14:156–163. - PubMed
- Forastiere A, Orringer M, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J Clin Oncol. 1993;11:1118–1123. - PubMed
- Kavanagh B, Anscher M, Leopold K, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984–1990. Int J Radiat Oncol Biol Phys. 1992;24:633–642. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials